Advertisement

Gene Therapy

  • Manzoor M. Khan
Chapter

Introduction

Although considered a modern therapeutic procedure, the theory of gene therapy goes back many decades. Historically, gene therapy has always been a part of science fiction with hope that its clinical applications will be realized. In the literature, these proposals go back many decades, and many have not yet been achieved. In ancient cultures, breeding plants and animals for certain goals was a way of life. Selective breeding practices were established before the development of modern genetics. The transfer of genes within DNA was first reported by Avery, Macleod and McCarthy in 1944, and a few years later, it was observed that viruses possess the ability to transfer genes. On the basis of the ability of viruses to transfer genes, Tatum in 1966 hypothesized the role of viruses in gene therapy and the possibility of isolating or synthesizing genes and inserting them into the organs with defective genes. Aposhian in 1969 suggested the use of genes in place of drugs to treat...

Keywords

Cystic Fibrosis Gene Therapy Gene Delivery Cystic Fibrosis Transmembrane Conductance Regulator Atrial Natriuretic Peptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Bibliography

  1. Alba R, Bosch A, Chillou M. 2005. Gutless adenovirus: Last generation adenovirus for gene therapy. Gene Ther. 12:518–527.CrossRefGoogle Scholar
  2. Alemany R. 2007. Cancer selective adenoviruses. Mol Aspects Med. 28:42–58.PubMedCrossRefGoogle Scholar
  3. Amalfitano A, Parks RJ. 2002. Separating fact from fiction: Assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr Gene Ther. 2:111–133.PubMedCrossRefGoogle Scholar
  4. Anderson WF, Fletcher JC. 1980. Gene therapy in human beings: When is it ethical to bring? NEJM. 303:1293–1297.PubMedCrossRefGoogle Scholar
  5. Anderson WF. 1984. Prospects for human gene therapy. Science. 226:401–409.PubMedCrossRefGoogle Scholar
  6. Anderson WF. 1992. Human gene therapy. Science. 256:808–813.PubMedCrossRefGoogle Scholar
  7. Anson DS, Smith GJ, Parsons DW. 2006. Gene therapy for cystic fibrosis airway disease – Is clinical success imminent? Curr Gene Ther. 6:161–179.PubMedCrossRefGoogle Scholar
  8. Baum C, Dullmann J, Li Z, Fehse B, et al. 2003. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 101:2099–2114.PubMedCrossRefGoogle Scholar
  9. Blaese RM, Culver KW, Miller AD, Carter CS, et al. 1995. T lymphocyte directed gene therapy for ADA deficiency SCID: Initial trial results after four years. Science. 270:475–480.PubMedCrossRefGoogle Scholar
  10. Boucher RC. 1999. Status of gene therapy for cystic fibrosis lung disease. J Clin Inv. 103:441–445.CrossRefGoogle Scholar
  11. Brand TC, Tolcher AW. 2006. Management of high risk metastatic prostate cancer: The case for novel therapies. J Urol. 176:576–580.CrossRefGoogle Scholar
  12. Brunetti-Pierri N, Ng P. 2006. Progress towards the application of helper-dependent adenoviral vectors for liver and lung gene therapy. Curr Opin Mol Ther. 8:446–454.PubMedGoogle Scholar
  13. Caplen NJ. 2003. RNA1 as a gene therapy approach. Expert Opin Biol Ther 3:575–586.PubMedCrossRefGoogle Scholar
  14. Cavazzana-Calvo M, Thrasher A, Mavilio F. 2004. The future of gene therapy. Nature. 427:779–781.PubMedCrossRefGoogle Scholar
  15. Cavazzana-Calvo M, Fischer A. 2007. Gene therapy for severe combined immunodeficiency: Are we there yet? J Clin Inv. 117:1456–1465.CrossRefGoogle Scholar
  16. Crittenden M, Gough M, Chester J, Kottle T, et al. 2003. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res. 63:3173–3180.PubMedGoogle Scholar
  17. Culver KW. 1996. Gene Therapy. A Primer for Physicians, Mary Ann Liebert Inc., New York.Google Scholar
  18. DiPaola RS, Plante M, Kaufman H, Petrylak DP, et al. 2006. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1 and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 4:1–1.PubMedCrossRefGoogle Scholar
  19. Djordjevic M. 2007. SELEX experiments: New prospects, applications and data analysis in inferring regulatory pathways. Biomol Eng. 24:179–189.PubMedCrossRefGoogle Scholar
  20. Dodge JA. 1998. Gene therapy for cystic fibrosis: What message for the recipient? Thorax. 53:157–158.PubMedCrossRefGoogle Scholar
  21. Eck SL, Wilson JM. 1996. Gene-based therapy. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE, et al., Eds. McGraw Hill, New York, pp. 77–1022.Google Scholar
  22. Editorial, 1997. Supervising gene therapy openly. Lancet. 350:79.Google Scholar
  23. Einfeld DA, Roelvink PW. 2002. Advances towards targetable adenovirus targetable adenovirus vectors for gene therapy. Curr Opin Mol Ther. 4:444–451.PubMedGoogle Scholar
  24. Epstein AL, Marconi P, Argnani R, Manservigi R. 2005. HSV-1 derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr Gene Ther. 5:445–448.PubMedCrossRefGoogle Scholar
  25. Flotte TR, Carter BJ. 1997. In vivo gene therapy associated with adeno-associated virus vectors for cystic fibrosis. Adv. Pharmacol. 40:85–101.PubMedCrossRefGoogle Scholar
  26. Freidmann T. 1989. Progress toward human gene therapy. Science. 244:1275–1281.CrossRefGoogle Scholar
  27. Fuch M. 2006. Gene therapy: An ethical profile of a new medical territory. J Gene Med. 8:1358–1362.CrossRefGoogle Scholar
  28. Galanis E, Vile R, Russell SJ. 2001. Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors. Crit Rev Oncol Hematol. 38:177–192.PubMedCrossRefGoogle Scholar
  29. Galanis E, Okuno SH, Nascimento AG, Lewis BD, et al. 2005. Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 12:437–445.PubMedCrossRefGoogle Scholar
  30. Gardlik R, Palffy R, Hodosy J, Lukacs J, et al. 2005. Vectors and delivery systems in gene therapy. Med Sci Monitor. 11:RA110–121.Google Scholar
  31. Gordon EM, Lopez FF, Cornelio GH, Lorenzo CC, et al. 2006. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: Three year clinical experience. Int J Oncol. 29:1053–1064.PubMedGoogle Scholar
  32. Gordon EM, Chan MT, Geraldino N, Lopez FF, et al. 2007. Le morte du tumour: Histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. Int J Oncol. 30:1297–1307.PubMedGoogle Scholar
  33. Gutermann A, Mayer E, von-Dehn-Rothfelser K, Breidenstein C, et al. 2006. Efficacy of oncolytic herpes virus NV1020 can be enhanced in combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther. 17:1241–1253.Google Scholar
  34. Harris JD, Evans V, Owen JS. 2006. ApoE gene therapy to treat hyperlipidemia and atherosclerosis. Curr Opin Mol Ther. 8:275–287.PubMedGoogle Scholar
  35. Hege KM, Jooss K, Pardoll D. 2006. GM-CSF gene modified cancer cell immunotherapies: Of mice and men. Int Rev Immunol. 25:321–352.PubMedCrossRefGoogle Scholar
  36. Hermonat PL, Mehta JL. 2004. Potential of gene therapy for myocardial ischemia. Curr Opin Cariol. 19:517–523.CrossRefGoogle Scholar
  37. Joyner A, Keller G, Phillips RA, Bernstein A. 1983. Retrovirus transfer of a bacterial gene into mouse hematopoietic progenitor cells. Nature. 305:556–558.PubMedCrossRefGoogle Scholar
  38. Kaiser J. 2005. Gene therapy. Putting the fingers on gene repair. Science. 310:1894–1896.PubMedCrossRefGoogle Scholar
  39. Kanai R, Tomita H, Hirose Y, Ohba S, et al. 2007. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP345 under the transcriptional control of musashi 1 promoter in the treatment of malignant glioma. Hum Gene Ther. 18:63–73.PubMedCrossRefGoogle Scholar
  40. Kanerva A, Hemminki A. 2005. Adenoviruses for treatment of cancer. Ann Med. 37:33–43.PubMedCrossRefGoogle Scholar
  41. Kaplan JM. 2005. Adenovirus based cancer gene therapy. Curr Gene Ther. 5:595–605.PubMedCrossRefGoogle Scholar
  42. Katz B, Goldbaum M. 2006. Macugen (pegaptanib sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF). Int Opthamol Clin. 46:141–154.CrossRefGoogle Scholar
  43. Kaufman HL, Cohen S, Cheung K, DeRaffele G, et al. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther. 17:239–244.Google Scholar
  44. Kay MA, Liu D, Hoogerbrugge G. 1997. Gene therapy. Proc Nat Acad Sci. USA. 94:12744–12746.Google Scholar
  45. Kay MA, Glorioso JC, Naldini L. 2001. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med. 7:33–40.PubMedCrossRefGoogle Scholar
  46. Kemeny N, Brown K, Covey A, Kim T, et al. 2006. Phase I. Open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther. 17:1214–1224.PubMedCrossRefGoogle Scholar
  47. Kim HJ, Jang SY, Park JI, Byun J, eet al. 2004. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med. 36:336–344.PubMedGoogle Scholar
  48. Kolb M, Martin G, Medina M, Ask K, et al. 2006. Gene therapy for pulmonary diseases. Chest. 130:879–884.PubMedCrossRefGoogle Scholar
  49. Kootstra NA, Verma IM. 2003. Gene therapy with viral vectors. Ann Rev Pharmacol Toxicol. 43:413–439.CrossRefGoogle Scholar
  50. Kudo-Saito C, Wansley EK, Gruys ME, Wiltrout R, et al. 2007. Combination therapy of an orthotropic renal cell carcinoma model using intratumoral vector-mediated costimulation of systemic interleukin-2. Clin Canc Res. 13:1936–1946.CrossRefGoogle Scholar
  51. Kyte JA, Mu L, Aamadal S, Kvalheim G, et al. 2006. Phase I/II trial of melanoma therapy with dendritic cells transfected with tumor-RNA. Cancer Gene Ther. 13:905–918.PubMedCrossRefGoogle Scholar
  52. Levine BL, Humeau LM, Boyer J, Rebello T, et al. 2006. Gene transfer in humans using a conditionally replicating lentiviral vector. PNAS. 103:17372–17377.PubMedCrossRefGoogle Scholar
  53. Levy B, Panicalli D, Marshall J. 2004. TRICOM: Enhanced vaccine as anticancer therapy. Exp Rev Vaccines. 3:397–402.CrossRefGoogle Scholar
  54. Li D, Jiang W, Bishop S, Ralston R, et al. 1999. Combination surgery and nonviral Interleukin-2 gene therapy for head and neck cancer. Clin Cancer Res. 5:1551–1556.PubMedGoogle Scholar
  55. Li D, Shugert E, Guo M, Bishop JS, et al. 2001. Combination non viral interleukin-2 and interleukin-12 gene therapy for head and neck squamous cell carcinoma. 127:1319–1324.Google Scholar
  56. Li M, Li H, Rossi JJ. 2006. RNAi in combination with ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann NY Acad Sci. 1082:172–179.PubMedCrossRefGoogle Scholar
  57. Li SD, Huang L. 2006. Gene therapy progress and prospects. Gene Ther. 13:1313–1319.PubMedCrossRefGoogle Scholar
  58. Liu L, Liu H, Visner G, Fletcher BS. 2006. Sleeping beauty-mediated eNOS gene therapy attenuates monocrotaline-induced pulmonary hypertension in rats. FASEB J. 20:2594–2596.PubMedCrossRefGoogle Scholar
  59. Lou E, Marshall J, Aklilu M, Cole D, et al. 2006. A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastasis of colorectal carcinoma. Clin Colorectal Cancer 5:368–371.PubMedCrossRefGoogle Scholar
  60. Lu X, Yu Q, Binder GK, Chen Z, et al. 2004. Antisense-mediated inhibition of human immunodeficiency virus replication by use of an HIV type I based vector results in severely attenuated mutants incapable of developing resistance. J Virol. 78:7079–7088.PubMedCrossRefGoogle Scholar
  61. Lundstrom K, boulikas T. 2003. Viral and nonviral vectors in gene therapy: Technology development and clinical trials. Technol Canc Res Treat. 2:471–486.Google Scholar
  62. Luque F, Oya R, Macias D, Saniger L. 2005. Gene therapy for HIV infection: Are lethal genes a valuable tool? Cell Mol Biol. 51:93–101.PubMedGoogle Scholar
  63. Madan RA, Arlen PM, Gulley JL. 2007. PANVAC-VF: Poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther 7:543–544.PubMedCrossRefGoogle Scholar
  64. Mann R, Mulligan RC, Baltimore D. 1983. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell. 33:153–159.PubMedCrossRefGoogle Scholar
  65. Marathe JG, Wooley DP. 2007. Is gene therapy a good therapeutic approach for HIV positive patients? Genet Vaccines Ther 5:5–5.PubMedCrossRefGoogle Scholar
  66. McConnell MJ, Imperiale MJ. 2004. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther. 15:1022–1033.PubMedCrossRefGoogle Scholar
  67. McLaughlin JM, McCarty TM, Cunningham C, Clark V, et al. 2005. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: Surgical experience and long term followup. Ann Surg Oncol. 12:825–830.CrossRefGoogle Scholar
  68. Middleton PG, Alton EW. 1998. Gene therapy for cystic fibrosis: Which postman, which box? Thorax. 53:197–199.PubMedCrossRefGoogle Scholar
  69. Miller AD, Jolly DJ, Friedmann T, Verma IM. 1983. A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): Gene transfer into cells obtained from human deficient in HPRT. Proc Nat Acad Sci USA. 80:4709–4713.Google Scholar
  70. Miller AD. 1992. Human gene therapy come of age. Nature. 357:455–460.PubMedCrossRefGoogle Scholar
  71. Neff T, Beard BC, Kiem HP. 2006. Survival of the fittest in vivo selection and stem cell gene therapy. Blood. 107:1751–1760.PubMedCrossRefGoogle Scholar
  72. Nemunaitis J. 2005. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Exp Rev Vaccines. 4:259–274.CrossRefGoogle Scholar
  73. Nemunaitis J, Murray N. 2006. Immune-modulating vaccines in non-small cell lung cancer. J Thorac Oncol. 1:756–761.PubMedCrossRefGoogle Scholar
  74. Nemunaitis J, Nemunaitis J. 2007. A review of vaccine clinical trials for non-small cell lung cancer. Exp Opin Biol Ther. 7:89–102.CrossRefGoogle Scholar
  75. Niidome T, Huang L. 2002. Gene therapy progress and prospects: Nonviral vectors. Gene Ther. 9:1647–1652.PubMedCrossRefGoogle Scholar
  76. Noe F, Nissinen J, Pitkanen A, Gobbi M., et al. 2007. Gene therapy in epilepsy, the focus on HPY. Peptides. 28:377–383PubMedCrossRefGoogle Scholar
  77. Osterman JV, Waddell A, Aposhian HV. 1970. DNA and gene therapy: Uncoating of polyoma pseudovirus in mouse embryo cells. Proc Nat Acad Sci USA. 67:37–40.Google Scholar
  78. Palmer DH, Young LS, Mautner V. 2006. Cancer gene therapy: Clinical trials. Trends Biotechnol. 24:76–82.PubMedCrossRefGoogle Scholar
  79. Petrulio CA, Kaufman HL. 2006. Development of the PANVAC-VF vaccine for pancreatic cancer. Exp Rev Vaccines 5:9–19.CrossRefGoogle Scholar
  80. Philpott NJ, Thrasher AJ. 2007. Use of nonintegrating lentiviral vectors for gene therapy. Hum Gene Ther. 18:483–489.PubMedCrossRefGoogle Scholar
  81. Pickles RJ. 2004. Physical and biological barriers to viral vector-mediated delivery of genes to the airway epithelium. Proc Am Thorac Soc. 1:302–308.Google Scholar
  82. Ponnazhagam S, Curiel DT, Shaw DR, Alvarez RD, et al. 2001. Adeno-associated virus for cancer gene therapy. Canc Res. 61:6313–6321.Google Scholar
  83. Poreteus MH, Connelly JP, Pruett SM. 2006. A look to future directions in gene therapy research. PLOS Genet. 2:133–2141.CrossRefGoogle Scholar
  84. Prchal JT. 2003. Delivery on demand – A new era of gene therapy? NEJM. 348:1282–1283.PubMedCrossRefGoogle Scholar
  85. Preuss MA, Curiel DT. 2007. Gene therapy: Science fiction or reality? South Med J. 100:101–104.PubMedCrossRefGoogle Scholar
  86. Puck JM, Malech HL. 2006. Gene therapy for immune disorders: Good news tampered by bad news. J All Clin Immunol. 117:865–869.CrossRefGoogle Scholar
  87. Puddu GM, Cravero E, Ferrari E, Muscari A, et al. 2007. Gene based therapy for hypertension – Do preclinical data suggest a promising future? Cardiology. 108:40–47.PubMedCrossRefGoogle Scholar
  88. Puhlmann M, Brown CK, Gnant M, Huang J, et al. 2000. Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 7:66–73.PubMedCrossRefGoogle Scholar
  89. Qian SH, Channon K, Neplioueva V, Wang Q, et al. 2001. Improved adenoviral vector for vascular gene therapy. Circ Res. 88:911–917.PubMedCrossRefGoogle Scholar
  90. Que NS, Sallenger BA. 2007. Gene therapy progress and prospects; RNA aptamers. Gene Ther. 14:283–291.CrossRefGoogle Scholar
  91. Que-Gewirth NS, Sullenger BA. 2007. Gene therapy progress and prospects: RNA aptamers. Gene Ther. 14:283–291.PubMedCrossRefGoogle Scholar
  92. Rainov NG, Ren H. 2003. Clinical trials with retrovirus mediated gene therapy – What have we learned? J Neurooncol. 65:227–236.PubMedCrossRefGoogle Scholar
  93. Raizada MK, Der-Sarkissian S. 2006. Potential of gene therapy strategy for the treatment of hypertension. Hypertension. 47:6–9.PubMedCrossRefGoogle Scholar
  94. Ramqvist T, Andreasson K, Dalianis T. 2007. Vaccination, immune and gene therapy based on virus-like particles against viral infection and cancer. Exp Opin Biol Ther 7:997–1007.CrossRefGoogle Scholar
  95. Rein DT, Breidenbach M, Curiel DT. 2006. Current developments in adenovirus based cancer gene therapy. Future Oncol. 2:137–143.PubMedCrossRefGoogle Scholar
  96. Romano G. 2006. The controversial role of adenoviral-derived vectors in gene therapy programs: Where do we stand? Drug News Persp. 19:99–106.CrossRefGoogle Scholar
  97. Rosenecker J, Huth S, Rudolph C. 2006. Gene therapy for cystic fibrosis lung disease: Current status and future perspectives. Curr Opin Mol Ther. 8:439–445.PubMedGoogle Scholar
  98. Sabbioni S, Callegari E, Manservigi M, Argnani R, et al. 2007. Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA. Gene Ther. 14:459–464.PubMedCrossRefGoogle Scholar
  99. Salmons B, Gunzburg WH. 1993. Targeting of retroviral vectors for gene therapy. Hum Gene Ther. 4:129–141.PubMedCrossRefGoogle Scholar
  100. Schillinger KJ, Tsai SY, Taffet GE, Reddy AK, et al. 2006. Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc Nat Acad Sci USA. 27:13789–13794.Google Scholar
  101. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, et al. 204. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors. J Clin Oncol. 22:592–601.Google Scholar
  102. Shen Y, Nemunaitis J. 2006. Herpes simplex virus 1 (SHV-1) for cancer treatment. Cancer Gene Ther. 13:975–992.PubMedCrossRefGoogle Scholar
  103. Shichiri M, Tanaka A, Hirata Y. 2003. Intravenous gene therapy for familial hypercholesterolemia using ligand facilitated transfer of liposomes LDL receptor gene complex. Gene Ther. 10:827–831.PubMedCrossRefGoogle Scholar
  104. Simon JW, Sacks N. 2006. Granulocyte-macrophage colony stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer. Urol Oncol. 24:419–424.CrossRefGoogle Scholar
  105. Small EJ, Sacks N, Neumanitis J, Urba WJ, et al. 2007. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 13:3883–3891.PubMedCrossRefGoogle Scholar
  106. Song S, Morgan M, Ellis T, Poirier A, et al. 1998. Sustained secretion of human-alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Nat Acad Sci. 95:14384–14388.Google Scholar
  107. Tan PH, Tan PL, George AJ, Chan CL. 2006. Gene therapy for transplantation for viral vectors – How much of the promise has been realized? Expert Opin Biol Ther. 6:759–772.PubMedCrossRefGoogle Scholar
  108. Tatum EL. 1966. Molecular biology, nucleic acids and the future of medicine. Persp Biol Med. 10:19–32.Google Scholar
  109. Thomson L. 1994. Correcting the Code: Inventing and Genetic Cure for Human Body. Simon and Schuster, New York. pp.189–267.Google Scholar
  110. Tomanin R, Scarpa M. 2004. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther. 4:357–372.PubMedGoogle Scholar
  111. Tsai TH, Chen SL, Xiao X, Chiang YH, et al. 2006. Gene therapy of focal cerebral ischemia using defective recombinant adeno-associated virus vectors. Front Biosci. 11:2061–2070.PubMedCrossRefGoogle Scholar
  112. Vahakangas E, Yla-Herttuala S. 2005. Gene therapy of atherosclerosis. Handbook Exp Pharm. 170:785–807.CrossRefGoogle Scholar
  113. Verma IM, Weitzman MD. 2005. Gene therapy twenty first century medicine. Ann Rev Biochem. 74:711–738.PubMedCrossRefGoogle Scholar
  114. Von-Laer D, Hasselmann S, Hasselmann K. 2006. Gene therapy for HIV infection: What does it need to make it work? J Gene Med 8:658–667.Google Scholar
  115. Vorburger SA, Hunt KK. 2002. Adenoviral gene therapy. The Oncologist 7:46–59.PubMedCrossRefGoogle Scholar
  116. Watanabe S, Temin HM. 1983. Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors. Mol Cell Biol. 3:2241–2249.PubMedGoogle Scholar
  117. Weber E, Anderson WF, Kasahara N. 2001. Recent advances in retrovirus vector-mediated gene therapy: Teaching an old vector new tricks. Curr Opin Mol Ther. 3:439–453.PubMedGoogle Scholar
  118. White AF, Ponnazhagan S. 2006. Airway epithelium directed gene therapy for cystic fibrosis. Med Chem. 2:499–503.PubMedCrossRefGoogle Scholar
  119. Wigler M, Silverstein S, Lee LS, Pellicer A, et al. 1977. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell. 11:223–232.PubMedCrossRefGoogle Scholar
  120. Wolff JA. 1994. Gene Therapeutics: Methods and Applications of Direct Gene Transfer. Birkhauser, Boston, MA.Google Scholar
  121. Wolff JA, Lederberg J. 1994. An early history of gene transfer and therapy. Hum Gene Ther. 5:469–480.PubMedCrossRefGoogle Scholar
  122. Woods NB, Ooka A, Karlsson S. 2002. Development of gene therapy for hematopoietic stem cells using lentiviral vectors. Leukemia. 16:563–569.PubMedCrossRefGoogle Scholar
  123. Xiao W, Chirmule N, Berta SC, McCullough B, et al. 1999. Gene therapy vectors based on adeno-associated virus type 1. J Virol. 73:3994–4003.PubMedGoogle Scholar
  124. Young LS, Mautner V. 2001. The promise and potential hazards of adenovirus gene therapy. Gut. 48:733–736.PubMedCrossRefGoogle Scholar
  125. Young LS, Searle PF, Onion D, Mautner V. 2006. Viral gene therapy strategies. J Pathol. 208:299–318.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Creighton University Medical CenterOmahaUSA

Personalised recommendations